References
- Bessler W. G., Jung G. Synthetic lipopeptides as novel adjuvants. Res. Immunol 1992; 143: 548–553, discussion 579–580[INFOTRIEVE], [CSA]
- Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol 2004; 4: 941–952, [INFOTRIEVE], [CSA], [CROSSREF]
- Hertz C. J., Kiertscher S. M., Godowski P. J., Bouis D. A., Norgard M. V., Roth M. D., Modlin R. L. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J. Immunol 2001; 166: 2444–2450, [INFOTRIEVE], [CSA]
- Knutson K. L. “Cancer vaccines: The next generation”. Drug discov. today. Therapeutic Strategies 2005; 2: 323–330, [CSA], [CROSSREF]
- Maurer-Gebhard M., Schmidt M., Azemar M., Altenschmidt U., Stocklin E., Wels W., Groner B. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 1998; 58: 2661–2666, [INFOTRIEVE], [CSA]
- Roth A., Espuelas S., Thumann C., Frisch B., Schuber F. Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes. Bioconjug. Chem 2004; 15: 541–553, [INFOTRIEVE], [CSA], [CROSSREF]
- Roth A., Rohrbach F., Weth R., Frisch B., Schuber F., Wels W. S. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br. J. Cancer 2005; 92: 1421–1429, [INFOTRIEVE], [CSA], [CROSSREF]
- Sieling P. A., Chung W., Duong B. T., Godowski P. J., Modlin R. L. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol 2003; 170: 194–200, [INFOTRIEVE], [CSA]
- Takeda K., Takeuchi O., Akira S. Recognition of lipopeptides by Toll-like receptors. J. Endotoxin Res 2002; 8: 459–463, [INFOTRIEVE], [CSA], [CROSSREF]
- Van Der Bruggen P., Van Den Eynde B. J. Processing and presentation of tumor antigens and vaccination strategies. Curr. Opin. Immunol 2006; 18: 98–104, [INFOTRIEVE], [CSA], [CROSSREF]
- Van Der Bruggen P., Zhang Y., Chaux P., Stroobant V., Panichelli C., Schultz E. S., Chapiro J., Van Den Eynde B. J., Brasseur F., Boon T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev 2002; 188: 51–64, [INFOTRIEVE], [CSA], [CROSSREF]
- Wang H. Y., Wang R. F. Antigen-specific CD4+ regulatory T cells in cancer: implications for immunotherapy. Microbes Infect 2005; 7: 1056–1062, [INFOTRIEVE], [CSA], [CROSSREF]
- Wiesmuller K. H., Bessler W., Jung G. Synthesis of the mitogenic S-[2,3-bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide from Escherichia coli lipoprotein. Hoppe-Seyler’s Z Physiol. Chem 1983; 364: 593–606, [CSA]